EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade,
pembrolizumab and EZH2 inhibitor, tazemetostat combination therapy for patients with advanced
non-small cell lung cancer who have progressed from front or second-line treatment. Patients
will be enrolled at multiple Veterans Affairs Medical Centers.